Show simple item record

dc.contributor.authorCheadle, Eleanor J
dc.date.accessioned2009-07-07T09:48:05Z
dc.date.available2009-07-07T09:48:05Z
dc.date.issued2006-02
dc.identifier.citationMT-103 Micromet/MedImmune. 2006, 8 (1):62-8 Curr. Opin. Mol. Ther.en
dc.identifier.issn1464-8431
dc.identifier.pmid16506527
dc.identifier.urihttp://hdl.handle.net/10541/72697
dc.description.abstractMicromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
dc.language.isoenen
dc.subject.meshAnimals
dc.subject.meshAntibodies, Bispecific
dc.subject.meshClinical Trials, Phase I as Topic
dc.subject.meshDrug Industry
dc.subject.meshHumans
dc.subject.meshLymphoma, B-Cell
dc.subject.meshStructure-Activity Relationship
dc.titleMT-103 Micromet/MedImmune.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uken
dc.identifier.journalCurrent Opinion in Molecular Therapeuticsen
html.description.abstractMicromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.


This item appears in the following Collection(s)

Show simple item record